A Prospective, Randomized, Double-blind, Phase II Study to Evaluate the Safety and Efficacy of Topical Thrombin (Human) Grifols as an Adjunct to Hemostasis durning Vascular, Parenchymous, Soft Tissue, and Spinal Open Surgeries

StatusFinished
Effective start/end date2/05/1431/05/19

Funding

  • Grifols, Inc: $51,489.25

Keywords

  • Biotechnology & Drug Development, Cardiovascular Research